Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2690 participants.
Also called NCT04937699
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,690 participants
- Registry
-
NCT04937699
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT04937699. Randomized; no masking; primary purpose treatment. Start 2023-03-28 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
- Acronym
- MATE
- Condition
- Acute Coronary Syndrome
- Condition
- Percutaneous Coronary Intervention
- Intervention (Drug)
- Standard-DAPT of Ticagrelor plus aspirin
- Intervention (Drug)
- Sequential monotherapy of Ticagrelor and clopidogrel
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Record details
- Record id
cardio:ct-nct04937699- Content hash
4459547b1745c6f93f33221687c99a2960436768640e1be847c17fb94e663661